Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 5

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1A
Chunk 5
---
 cash since inception. For the year ended December 31, 2024, we reported a net operating
cash outflow of $5.6 million and a net cash inflow from financing activities of $3.8 million. For the year ended December 31, 2023, we
reported a net operating cash outflow of $4.5 million and a net cash inflow from financing activities of $8.8 million.

Research
and development, and general and administrative expenses, and cash used for operations will continue to be significant and may increase
substantially in the future in connection with new research and development initiatives and continued product commercialization efforts.
We may need to raise additional capital to fund our operations, continue to conduct clinical trials to support potential regulatory approval
of marketing applications and to fund commercialization of our products.

The
amount and timing of our future funding requirements will depend on many factors, including, but not limited to:

    ●
    the
    timing of FDA approval, if any;

    ●
    the
    DEA continuing to classify Ketamir-2 as a substance not subject to CSA;

    ●
    the
    DEA continuing to classify MIRA-55 as a substance not subject to CSA;

    ●
    the
    timing and amount of revenue from sales of our products, or revenue from grants or other sources;

    ●
    the
    rate of progress and cost of our clinical trials and other product development programs;

    ●
    costs
    of establishing or outsourcing sales, marketing, and distribution capabilities;

    ●
    costs
    and timing of completion of expanded in-house manufacturing facilities as well as any outsourced commercial manufacturing supply
    arrangements for our product candidates;

    ●
    costs
    of filing, prosecuting, defending, and enforcing any patent claims and other intellectual property rights associated with our product
    candidates;

    ●
    costs
    of operating as a U.S. public company;

    ●
    the
    effect of competing technological and market developments;

    ●
    personnel,
    facilities, and equipment requirements; and

    ●
    the
    terms and timing of any additional collaborative, licensing, co-promotion, or other arrangements that we may establish.

While
we expect to fund our future capital requirements from a number of sources including existing cash balances, future cash flows from operations
and the proceeds from further public offerings, we cannot assure you that any of these funding sources will be available